Researchers Prepare to Discuss Cancer Progression and Cell Death in two Keystone Symposia

Registration Open for Event Organized by Associate Director at The Cancer Institute of New Jersey
October 27, 2009

New Brunswick, N.J.– Basic scientists from around the globe are set to converge upon Vancouver, British Columbia, March 12 through 17, 2010, to discuss the latest discoveries in cancer research.  Co-organizing both upcoming Keystone Symposia is Eileen White, PhD, associate director for basic science at The Cancer Institute of New Jersey (CINJ), who is internationally recognized for her work in programmed cell death (apoptosis) and cell self-digestion (autophagy). CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

The conferences held by the non-profit organization Keystone Symposia, are designed to provide scientific leaders an opportunity for debate, exchange, and learning and to serve as a vehicle for scientists to “discuss emerging discoveries and their application to improving cancer therapy.”  The conference topics for the March event, “Metabolism and Cancer Progression” and “Cell Death Pathways: Apoptosis, Autophagy and Necrosis,” will focus on new approaches to cancer therapy.

Dr. White, who is also an adjunct professor of surgery at UMDNJ-Robert Wood Johnson Medical School, and a professor of molecular biology and biochemistry at Rutgers University, notes the event presents a unique opportunity for collaboration, since scientists are able to interact with one another after hearing first hand about the groundbreaking work their colleagues are engaged in across the globe. 

Additional information on the conference can be found at   The deadline for early registration is January 12, 2010.

About The Cancer Institute of New Jersey

The Cancer Institute of New Jersey is the state’s first and only National Cancer Institute-designated Comprehensive Cancer Center, and is dedicated to improving the prevention, detection, treatment and care of patients with cancer. CINJ’s physician-scientists engage in translational research, transforming their laboratory discoveries into clinical practice, quite literally bringing research to life. The Cancer Institute of New Jersey is a center of excellence of UMDNJ-Robert Wood Johnson Medical School. To support CINJ, please call the Cancer Institute of New Jersey Foundation at 1-888-333-CINJ.

The Cancer Institute of New Jersey Network is comprised of hospitals throughout the state and provides a mechanism to rapidly disseminate important discoveries into the community. Flagship Hospital: Robert Wood Johnson University Hospital. Major Clinical Research Affiliate Hospitals: Carol G. Simon Cancer Center at Morristown Memorial Hospital, Carol G. Simon Cancer Center at Overlook Hospital, and Jersey Shore University Medical Center. Affiliate Hospitals: Bayshore Community Hospital, CentraState Healthcare System, Cooper University Hospital*, JFK Medical Center, Mountainside Hospital, Raritan Bay Medical Center, Robert Wood Johnson University Hospital at Hamilton (CINJ at Hamilton), Saint Peter’s University Hospital, Somerset Medical Center, Southern Ocean County Hospital, The University Hospital/UMDNJ-New Jersey Medical School*, and University Medical Center at Princeton. *Academic Affiliate

About Rutgers University
Established in 1766, Rutgers, The State University of New Jersey, is America’s eighth oldest institution of higher learning and one of the nation’s premier public research universities.  Serving more than 50,000 students on campuses in Camden, Newark and New Brunswick, Rutgers offers more than 280 bachelor’s, master’s, doctoral and professional degree programs. The university is home to 27 degree-granting schools and colleges, and more than 150 specialized centers and institutes. 



Michele Fisher


precision medicine at Rutgers Cancer Institute







Donate Now








Proud member of
Big Ten Cancer Research Consortium



Rutgers Health